Optimal timing of surgical revascularization in patients with acute myocardial infarction

Abstract

Acute myocardial infarction (AMI) is the leading cause of cardiovascular mortality in developed countries. While primary percutaneous coronary intervention is the gold-standard first-line therapy for initial revascularization of a culprit vessel, coronary artery bypass grafting (CABG) surgery can allow for subsequent complete revascularization when additional high-risk coronary stenoses remain. The optimal timing of CABG after AMI remains controversial. Early surgery during the acute period can lead to a detrimental systemic inflammatory response and may be associated with a higher bleeding risk due to the use of antiplatelet and fibrinolytic agents. On the other hand, later surgery increases the risk of ischemic recurrence while waiting, with the potential for an irreversible decrease in myocardial function or death. This narrative review summarizes the evidence supporting decision-making for optimal timing of surgical revascularization in patients with AMI.

Keywords

Acute myocardial infarction / coronary artery bypass grafting / percutaneous coronary intervention / surgical timing optimization

References

[1] Barberi C.The use of cardiac troponin T (cTnT) in the postmortem diagnosis of acute myocardial infarction and sudden cardiac death: a systematic review.Forensic Sci Int2018;292:27-38

[2] Virani SS,Aparicio HJ.Heart disease and stroke statistics-2021 update: a report from the American heart association.Circulation2021;143:e254-743

[3] Ryan TJ,Antman EM.ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction).Circulation1996;94:2341-50

[4] Phillips SJ,Zeff RH.Emergency coronary artery revascularization: a possible therapy for acute myocardial infarction.Circulation1979;60:241-6

[5] Elbadawi A,Mahmoud K.Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction.JACC Cardiovasc Interv2019;12:1825-36

[6] Ouaddi NE,Labata C.Mechanical complications in STEMI: prevalence and mortality trends in the primary PCI era. The Ruti-STEMI registry.Rev Esp Cardiol2023;76:427-33

[7] Weiss ES,Joyce DL,Yuh DD.Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data.J Thorac Cardiovasc Surg2008;135:503-11.e3

[8] Abd-Alaal MM,Abbas OA,Al-Saddique A.Timing of revascularization after acute myocardial infarction.Asian Cardiovasc Thorac Ann2010;18:118-21

[9] Ngaage DL,Tang A.Early and late prognostic implications of coronary artery bypass timing after myocardial infarction.Eur J Cardiothorac Surg2013;43:549-54

[10] Grieshaber P,Oster L.Is delayed surgical revascularization in acute myocardial infarction useful or dangerous? New insights into an old problem..Interact Cardiovasc Thorac Surg2017;25:772-9

[11] Yau TH,Brigden ZM,Harky A.The timing of surgical revascularization in acute myocardial infarction: when should we intervene?.J Cardiovasc Surg2022;63:179-86

[12] Smilowitz NR.The history of primary angioplasty and stenting for acute myocardial infarction.Curr Cardiol Rep2016;18:5

[13] Julian DG.Treatment of cardiac arrest in acute myocardial ischaemia and infarction.Lancet1961;2:840-4

[14] De Caterina R,Bernini W.Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction.Am J Cardiol1985;55:589-90

[15] De Caterina R,Bernini W.Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function.Eur Heart J1985;6:409-17

[16] Montinari MR,De Caterina R.The first 3500 years of aspirin history from its roots - a concise summary.Vascul Pharmacol2019;113:1-8

[17] Fletcher AP,Smyrniotis FE.The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy.Trans Assoc Am Physician1958;71:287-96

[18] Yusuf S.Interventions that potentially limit myocardial infarct size: overview of clinical trials.Am J Cardiol1987;60:11A-7A

[19] Keon WJ,Shankar KR,Akyrekli Y.Emergency aorto-coronary venous bypass graft in cardiogenic shock.Can Med Assoc J1971;105:1293-6

[20] DeWood MA,Berg R Jr.Acute myocardial infarction: a decade of experience with surgical reperfusion in 701 patients.Circulation1983;68:Ii8-16

[21] Keon WJ,Shankar KR,Nino A.Experience with emergency aortocoronary bypass grafts in the presence of acute myocardial infarction.Circulation1973;48:III151-5

[22] Koshal A,Davies RA,Keon WJ.Urgent surgical reperfusion in acute evolving myocardial infarction. A randomized controlled study. Circulation 1988;78:I171-8.

[23] Grüntzig AR,Siegenthaler WE.Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.N Engl J Med1979;301:61-8

[24] Hartzler GO,McConahay DR.Percutaneous transluminal coronary angioplasty: application for acute myocardial infarction.Am J Cardiol1984;53:117C-21C

[25] Keeley EC,Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.Lancet2003;361:13-20

[26] Lawton JS,Bangalore S.2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.Circulation2022;145:e4-17

[27] Grines CL,Marco J.A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group.N Engl J Med1993;328:673-9

[28] Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction.N Engl J Med1997;336:1621-8

[29] Berger PB,Holmes DR Jr.Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial.Circulation1999;100:14-20

[30] Byrne RA,Coughlan JJ.ESC Scientific Document Group2023 ESC guidelines for the management of acute coronary syndromes.Eur Heart J2023;44:3720-826

[31] Bernard C,Jazayeri A.Optimal timing of coronary artery bypass grafting in haemodynamically stable patients after myocardial infarction.Biomedicines2023;11:979 PMCID:PMC10046680

[32] Biancari F,Rubino AS.Outcome of emergency coronary artery bypass grafting.J Cardiothorac Vasc Anesth2015;29:275-82

[33] Chen HL.Timing of coronary artery bypass graft surgery for acute myocardial infarction patients: a meta-analysis.Int J Cardiol2014;177:53-6

[34] Lang Q,Meng W.Appropriate timing of coronary artery bypass graft surgery for acute myocardial infarction patients: a meta-analysis.Front Cardiovasc Med2022;9:794925 PMCID:PMC8995744

[35] Maganti M,Yau TM,Badiwala M.Changing trends in emergency coronary bypass surgery.J Thorac Cardiovasc Surg2011;142:816-22

[36] Klempfner R,Younis A.Early referral to coronary artery bypass grafting following acute coronary syndrome, trends and outcomes from the acute coronary syndrome israeli survey (ACSIS) 2000-2010.Heart Lung Circ2018;27:175-82

[37] Lemaire A,Ikegami H,Verghis N.Delay in coronary artery bypass grafting for STEMI patients improves hospital morbidity and mortality.J Cardiothorac Surg2020;15:86 PMCID:PMC7216497

[38] Liakopoulos OJ,Wendt D.Surgical revascularization for acute coronary syndromes: a report from the North Rhine-Westphalia surgical myocardial infarction registry.Eur J Cardiothorac Surg2020;58:1137-44

[39] Thielmann M,Marr A.Predictors and outcomes of coronary artery bypass grafting in ST elevation myocardial infarction.Ann Thorac Surg2007;84:17-24

[40] Bianco V,Gleason TG.Timing of coronary artery bypass grafting after acute myocardial infarction may not influence mortality and readmissions.J Thorac Cardiovasc Surg2021;161:2056-64.e4

[41] Sintek CF,Khonsari S.Surgical revascularization after acute myocardial infarction.J Thorac Cardiovasc Surg1994;107:1317-22

[42] Fransen E,Dentener M,Geskes G.Systemic inflammation present in patients undergoing CABG without extracorporeal circulation.Chest1998;113:1290-5

[43] Anzai T,Shiraki H.C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction.Circulation1997;96:778-84

[44] Pietilä K,Pöyhönen L.C-reactive protein in subendocardial and transmural myocardial infarcts.Clin Chem1986;32:1596-7

[45] Parikh SV,Jessen ME.CRUSADE and ACTION Registry-GWTG ParticipantsTiming of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National cardiovascular data registry ACTION registry-GWTG (acute coronary treatment and intervention outcomes network registry-get with the guidelines).JACC Cardiovasc Interv2010;3:419-27

[46] Kite TA,Bountziouka V.Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials.Eur Heart J2022;43:3148-61 PMCID:PMC9433309

[47] Park DW,Schulte PJ.Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction.JAMA2014;312:2019-27

[48] Steg PG,Atar D.Task Force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology (ESC)ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J2012;33:2569-619

[49] Levine GN,Blankenship JC.2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction.J Am Coll Cardiol2016;67:1235-50

[50] De Innocentiis C, Zimarino M, De Caterina R. Is complete revascularisation mandated for all patients with multivessel coronary artery disease?.Interv Cardiol2018;13:45-50 PMCID:PMC5872375

[51] Windecker S,Alfonso F.2014 ESC/EACTS guidelines on myocardial revascularization.EuroIntervention2015;10:1024-94

[52] Vlaar PJ,Holmes DR Jr.Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis.J Am Coll Cardiol2011;58:692-703

[53] Ebrahimi R,Mehran R.Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.J Am Coll Cardiol2009;53:1965-72

[54] Fox KA,Peters R.Clopidogrel in unstable angina to prevent recurrent ischemic events trialBenefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) Trial.Circulation2004;110:1202-8

[55] Smith PK,Levy JH.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.J Am Coll Cardiol2012;60:388-96 PMCID:PMC3407327

[56] Valgimigli M,Byrne RA.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.Kardiol Pol2017;75:1217-99

[57] Mehta SR,Cantor WJ.members of the Secondary Panel2018 Canadian cardiovascular society/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy.Can J Cardiol2018;34:214-33

[58] Gherli R,Dalén M.Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting.JAMA Cardiol2016;1:921-8

[59] Schultz-Lebahn A,Pedersen TF,Hvas AM.Platelet function assessed by ROTEM(®)platelet in patients receiving antiplatelet therapy during cardiac and vascular surgery.Scand J Clin Lab Invest2022;82:18-27

[60] Sibbing D,Alexopoulos D.Updated expert consensus statement on platelet function and genetic testing for guiding p2Y(12) receptor inhibitor treatment in percutaneous coronary intervention.JACC Cardiovasc Interv2019;12:1521-37

[61] Bhatt DL,Weitz JI.Antibody-based ticagrelor reversal agent in healthy volunteers.N Engl J Med2019;380:1825-33

[62] Bhatt DL,Mazer CD.Bentracimab for ticagrelor reversal in patients undergoing urgent surgery.NEJM Evidence2022;1:3

[63] Douketis JD,Spencer FA.Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines.Chest2012;141:e326S-50S

[64] Alquwaizani M,Adams C.Anticoagulants: a review of the pharmacology, dosing, and complications.Curr Emerg Hosp Med Rep2013;1:83-97 PMCID:PMC3654192

[65] Hochman JS,Webb JG.Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock.N Engl J Med1999;341:625-34